Skip survey header

9132 A Day in the Life: IO for Liver Cancer Enduring Webinar

A Day in the Life: IO for Liver Cancer

Drs. Charles Kim, Robert Lewandowski, David Lu, Sharon Kwan, Matthew Scheidt
1. When discussing locoregional treatment options for treating HCC, what is the main reason why Y90 would be preferred over TACE based on randomized data? *This question is required.
Correct.
Explanation: Based on the study published by Salem R et al Gastroenterology 2016, Patients in the Y90 radioembolization group had significant longer median TTP (>26 mo) than patients in the cTACE group (6.8 mo; P = .0012) (hazard ratio, 0.122; 95% confidence interval [CI], 0.027-0.557; P = .007).
2. Which of the following is a risk factor for tract seeding for thermal ablation of liver tumors? *This question is required.
Correct.
Explanation: Whereas the incidence of tract seeding with percutaneous thermal ablation and biopsies is very low (<5%), Llovet et al reported in Hepatology 2001 that 36% of all subcapsular tumors had associated tract seeding after ablation.
3. When planning embolotherapy treatment for HCC in cirrhotic patients, which of the following is of equal importance as tumor destruction? *This question is required.
Correct.
Explanation: In patients with HCC and cirrhosis, both tumor progression and hepatic function deterioration are crucial determinants of patient survival.
 
4. When evaluating a patient’s candidacy for Y90, all of the following should raise concern for patient candidacy except: *This question is required.
Correct.
Explanation: Whereas A,B,D are negative predictors for patient prognosis after Y90, anticoagulation status has not been shown to be a negative predictor.